Listed by the USPTO as HAM, JIEUN
Tech Center 1600 • Art Units: 1600 1643 1645 1652
This examiner grants 46% of resolved cases
HAM, JIEUN is assigned to Tech Center 1600 and Art Unit 1600. The profile records 11 resolved cases, a 45.5% allowance rate, and a 1079-day median time to allowance. Interview lift is 0.0%. The small resolved-case record limits the strength of any broad inference, but it shows an observed allowance rate below half and no measured interview association with allowance.
The listed companies are Board of Regents of the University of Texas System, Korea Institute of Science and Technology, and Korea Advanced Institute of Science and Technology. The listed firms are NORTON ROSE FULBRIGHT US LLP, pH IP Law, and Apex Attorneys at Law, LLP. These names may help identify relevant prosecution experience. Counsel should emphasize written claim development and prepare for a lengthy timeline, without assuming that an interview will materially change the outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18300169 | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC PROTEINS AND METHODS OF USE | Final Rejection | Hoffmann-La Roche Inc. |
| 18039071 | EXOSOMES EXPRESSING RSVF AND USE THEREOF | Final Rejection | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17773658 | SMALL LIPID NANOPARTICLES, AND CANCER VACCINE INCLUDING SAME | Non-Final OA | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18565831 | METHODS OF USING ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T CELLS | Non-Final OA | Regents of the University of Minnesota |
| 18202066 | MAP KINASE PATHWAY TARGETS FOR THE TREATMENT OF MARFAN SYNDROME | Final Rejection | The Johns Hopkins University |
| 18491850 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18546682 | Inhibition of SLC4A4 in the Treatment of Cancer | Final Rejection | KATHOLIEKE UNIVERSITEIT LEUVEN |
| 18699702 | ENGINEERING NK CELLS WITH A CAR CONSTRUCT WITH OPTIMAL SIGNALING | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17904473 | CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTAU) AND USES THEREOF | Non-Final OA | Board of Regents, The University of Texas System |
| 18698343 | TREATMENT OF LUPUS | Non-Final OA | ASTRAZENECA AB |
| 18308778 | MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 | Non-Final OA | SANOFI |
| 18577912 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF MYASTHENIA GRAVIS | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 18549459 | METHOD FOR TREATING CANCER BY USING ANTIBODY-DRUG CONJUGATE AND USE | Final Rejection | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy45.5% of resolved applications examined by Jieun Ham were allowed (11 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jieun Ham took 1,079 days on average from filing to allowance.
Jieun Ham examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).